DOCSLIB.ORG

19 and GBS Onset SARS-Cov- 2 Testing Clinical Features (MRC Score)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
19 and GBS Onset SARS-Cov- 2 Testing Clinical Features (MRC Score) BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Author Patient Interval SARS-CoV- Clinical features Electro- CSF Ab to MRI Treatment/ No: COVID- 2 testing (MRC score) diagnosis gangliosides Response to treatment Age/ 19 and Sex GBS onset Zhao et al. 1,61/ F GBS as NPS + Paraparesis progressing in 3 days to AIDP ACD ND ND IVIG. Recovery in 30 days 4/1/2020 presenting tetraparesis (ULs 4/5, LLs 3/5), feature areflexia LLs, distal hypoesthesia Camdessanche 2,64/M 11 days NPS + Distal paresthesia progressing to AIDP ACD Negative ND IVIG. NR et al. tetraparesis (LLs 2/5, Uls 2-4/5) 4/15/2020 areflexia, dysphagia, and respiratory failure Sedaghat and 3,65/M 14 days NPS + Ascending tetraplegia (ULs 2-3/5, AMSAN ND ND Head and IVIG. NR Karimi LLs 1-2/5) bilateral facial palsy, cervical spine: 4/15/2020 areflexia, distal hypoesthesia non contributory Toscano et al. 4,77/F 7 days NPS + Distal paresthesia progressing to AMSAN ACD Negative Enhancement of 2 IVIG courses. Minimal 4/17/2020 tetraplegia, bulbar palsy, areflexia PCR- caudal roots improvement and repiratory failure 5,23/M 10 days NPS + Facial diplegia, LLs paresthesia, AMSAN ACD ND Enhancement of IVIG. Mild improvement of sensory ataxia, areflexia PCR- facial nerves facial weakness and disappearance of paresthesia 6,55/M 10 days NPS + Distal paresthesia, LLs weakness AMAN ACD Negative Enhancement of 2 IVIG courses. At 1 month progressing to tetraparesis, bilateral PCR- caudal roots still ventilated facial palsy, areflexia, respiratory failure 7,76/M 5 days NPS + LLs weakness progressing to AIDP Normal ND Head and spine: IVIG. Motor improvement tetraparesis PCR- normal but still unable to stand 8,61/M 7 days 2NPS – LLs paresthesia, tetraplegia, AIDP Normal Negative Spine normal IVIG, PE. At 1 month still Chest CT+ areflexia, facial weakness, dysphagia, PCR- tetraplegic and ventilated Serology + respiratory failure (IgG) Uncini A, et al. J Neurol Neurosurg Psychiatry 2020; 91:1105–1110. doi: 10.1136/jnnp-2020-324491 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Gutierrez- 9,50/ 5 days NPS + Ophthalmoparesis, perioral ND ACD GD1b (IgG) ND IVIG. Recovery in 2 weeks Ortiz et al. paresthesia, areflexia, gait ataxia PCR- 4/17/2020 10,39/ 3 days NPS+ Bilateral CN VI palsy,,areflexia ND ACD ND ND ND. Spontaneous recovery M PCR- in 2 weeks Virani et al. 11,54/ NR NPS+ Tetraparesis (ULs 3/5, LLs 2/5) ND ND ND Thoracic and IVIG. Recovery of 4/18/2020 M areflexia, urinary retention, lumbar spine: respiratory and Uls respiratory failure normal weakness in 10 days Galan et al. 12,43/ 10 NPS+ Tetraparesis (3-4/5), distal AIDP ND ND ND IVIG, favorable outcome 4/23/2020 M hypoesthesia, facial diplegia, dysphagia areflexia El Otmani et 13,70/F 3 days NPS+ Distal paresthesia progressing rapidly AMSAN ACD ND ND IVIG. No improvement after al. to tetraplegia. Areflexia PCR- 1 week 4/24/ 2020 Padroni et al.. 14,70/F 28 NPS+ Distal paresthesia and gait difficulties AIDP ACD ND ND IVIG. NR 4/24/2020 progressing to tetraparesis (distal Uls and LLs 4/5), areflexia, respiratory failure Coen et al. 32,70’/ 10 NPS+ Paraparesis, distal allodynia, AIDP ACD Negative Spine: normal IVIG. Rapid improvement 4/28/2020 M difficulty in voiding, constipation areflexia Alberti et al. 15,71/ NC NPS+ Distal paresthesia progressing to AIDP ACD ND ND IVIG. Death the day after 4/29/2020 M tetraplegia (Uls 3/5, LLs, 2/5), PCR- the admission. hypoesthesia at 4 limbs, areflexia, drug resistant hypertension, respiratory failure Arnaud et al. 16,64/ 16 days NPS+ Rapidly progressive paraparesis, AIDP ACD ND ND IVIG. Not better specified 5/11/2020 M distal proprioceptive loss at 4 limbs, PCR- “success” areflexia Ottaviani et al. 17,66/F 10 days 2nd NPS+ Paraplegia and mild Uls weakness AIDP ACD Negative ND IVIG. NR 5/12/2020 (4/5), areflexia. Progression with PCR- facial palsy, confusion and agitation, respiratory failure Caamaño and 18,61/ 10 days NPS+ Bilateral facial palsy ND ACD ND Head normal Low dose oral prednisone. Beato M PCR- Barely notable improvement 5/14/2020 after 2 weeks Uncini A, et al. J Neurol Neurosurg Psychiatry 2020; 91:1105–1110. doi: 10.1136/jnnp-2020-324491 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Gigli et al. 19,53/ NR 2 NPS- Paresthesiia, atxia AIDP ACD Negative N D NR 5/19/2020 M Chest CT+ PCR- Serology+ (IgM and IgG) Riva et al. 20,60’/ 20 days 2 NPS- Proximal LLs weakness (3-4/5) with AIDP Normal Negative Cervical spine: IVIG. Slow improvement 5/26/2020 M Chest CT+ severe position and proprioception PCR- normal Serology+ deficit, areflexia. Progression with (IgG) Uls involvement, facial diplegia and bulbar palsy Scheidl et al. 21,54/F 14 days NPS+ Paraparesis (3-4/5), distal paresthesia AIDP ACD ND Cervical spine: IVIG. Almost complete 5/26/2020 and sensory loss, areflexia, dysphagia normal recovery Fernandez- 22,74/F 12 NPS+ Gait ataxia and LLs areflexia Equivocal ACD Negative Head normal IVIG. Improvement of gait Dominguez et PCR- ataxia and reappearance of al. reflexes. 5/26/2020 Bigaut et al. 23,43/ 21 days NPS+ Distal LLs weakness, paresthesia, AIDP ACD Negative Cranial (III, IVIG, progressive 5/27/2020 M and hypoesthesia ascending to distal PCR- VI,VII, VIII) improvement Uls, hypoesthesia LLs, ataxia, neuritis, areflexia, facial palsy radiculitis and brachial and lumbar plexitis 24,70/F 10 days NPS+ Proximal tetraparesis, Uls and AIDP ACD ND ND IVIG. Slow progressive perioral paresthesia, areflexia, PCR- improvement respiratory failure Assini et al. 25,55/ 20 days NPS+ Bilateral CN III,V,IX,X,XII AIDP Normal Negative Head: normal IVIG. Rapid improvement 5/28/2020 M involvement. Hyporeflexia, PCR- and recovery respiratory failure 26,60/ 23 days NPS+ Weakness LLs, right foot drop, AMSAN Normal Negative ND IVIG. Rapid improvement M areflexia, gastroplegia, paralytic PCR- of dysautonomia ileus, loss of blood pressure control, respiratory failure. Lantos et al. 27,36/ 4 days NPS+ Partial lt CN III cranial nerve palsy, ND ND equivocal Enlargement IVIG.Improvement 5/28/2020 M paresthesia and hypostesia LLs, result to and ataxia.followed by bilateral CN VI Asialo-GM1 ehhancement palsy, hyporeflexia CN III Uncini A, et al. J Neurol Neurosurg Psychiatry 2020; 91:1105–1110. doi: 10.1136/jnnp-2020-324491 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Chan et al. 28,58/ GBS as NPS+ Facial diplegia, dysarthria, and distal AIDP ACD ND Bilateral CN VII IVIG. Minimal 5/29/2020 M presenting LLs paresthesia, areflexia enhancement improvement of facial feature diplegia at discharge Lascano et al. 29,52/F 15 4th NFS+ Back pain, limb weakness, distal AIDP ACD Negative Spine: no roots IVIG. At 5 weeks bedbound 6/1/2020 Serology + paresthesia, ataxia progressing to PCR- enhancement but able to stand up with (IgM,IgG) tetraplegia with areflexia, respiratory assistance. failure, dysautonomia 30,63/F 7 2nd NPS+ LLs pain, mild weakness evolving to AIDP Normal ND ND IVIG. Full motor recovery at tetraparesis, distal paresthesias and dismissal areflexia 31,61/F 22 NPS+ LL weakness distal paresthesia, AIDP ACD ND Head: normal IVIG. Improvement with bilateral facial palsy, dizziness, PCR- Lumbosacral regained ability to walk with dysphagia, dysautonomia, areflexia. roots assistance enhancement Oguz-Akarsu 33,53/F NC NPS+ LLs, weakness (4/5) and AIDP Normal ND Thickening and PE. Improvement in 2 et al. 6/4/2020 hypoesthesia, slight distal weakness PCR- hyperintensity weeks, able to walk without ULs, dysarthria of cervical and assistance lumbar roots Sancho- 34,56/F 15 days NPS+ Gait unsteadiness and hand AIDP ACD Negative Brainstem and IVIG. Significant Saldaña et al. paresthesia evolving to proximal PCR- cervical improvement in 2 weeks 6/9/2020 tetraparesis, head dtrop, bilateral leptomeningeal facial palsy, bulbar weakness, enhancement. areflexia Manganotti et 35,50/F 16 days NPS+ Ophtalmoplegia, ataxia, areflexia, ND ACD Negative Head: normal IVIG. Recovery in 7 days al. 6/11/2020 mild hypoesthesia CN V2-V3 Helbok et al. 36,68/ 14 days NPS- LLs distal paresthesia, dysesthesia AIDP ACD Negative Spine MRI: non IVIG (30 g) and PE. In 2 6/12/2020 M Chest CT+ and hyposthesia, ataxic stance and contributory months regained motility Serology+ inability to walk progressing to without significant tetraparesis (proximal 2/5, distal 4/5) assistance and respiratory failure Kilinc et al. 37,50/ 28 days Fecal PCR+ Facia diplegia, mild proximal AIDP Normal Negative ND IVIG. Facial diplegia and 6/13/2020 M Serology + weakness, impaired proprioception PCR- mild proximal weakness (IgM and LLs , areflexia, gait ataxia persisted after 2 weeks IgG) Webb et al. 38,57/ 7 days NPS+ Distal LLs paresthesia, difficulties in AIDP ACD Negative ND IVIG. Weaned off 6/14/2020 M standing progressing to tetraparesis PCR- ventilation (ULs 4/5, LLs 1-3/5) dysphagia and respiratory failure Uncini A, et al. J Neurol Neurosurg Psychiatry 2020; 91:1105–1110. doi: 10.1136/jnnp-2020-324491 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Rana et al.
Load more

Recommended publications
  • Cervical Schwannoma: Report of Four Cases
    25-Cervical_3-PRIMARY.qxd 7/10/12 5:22 PM Page 345 CASE REPORT Cervical Schwannoma: Report of Four Cases Rohaizam Jaafar, MD (UKM), Tang Ing Ping, MS ORL-HNS (UM), Doris Evelyn Jong Yah Hui, MS ORL-HNS (UKM), Tan Tee Yong, MS ORL-HNS (UM), Mohammad Zulkarnaen Ahmad Narihan, MPATH (UKM) School of Health Sciences, Health Campus, Hospital Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia. SUMMARY Physical examination revealed a 3 x 3 cm mass located at Extracranial schwannomas in the head and neck region are right lateral upper third of the cervical region. The mass was rare neoplasms. The tumours often present as asymptomatic, firm, mobile and non-tender. She had a right facial nerve slowly enlarging lateral neck masses and determination of palsy (House-Brackman Grade IV) due to a previous operation the nerve origin is not often made until the time of surgery. for a right acoustic neuroma in 2000 and a right supraorbital Preoperative diagnosis maybe aided by imaging studies such wound for a plexiform schwannoma in 2007. as magnetic resonance imaging or computed tomography, while open biopsy is no longer recommended. The accepted A computed tomography of the neck and thorax was treatment for these tumors is surgical resection with performed and showed a well defined, minimally enhancing preservation of the neural pathway. We report four cases of lesion at the left parapharyngeal space measuring 2.4 x 4.3 x cervical schwannomas that we encountered at our center 10 cm. The left carotid sheath vessel is displaced medially. during four years of period.
    [Show full text]
  • Case Report Head and Neck Schwannomas: a Surgical Challenge—A Series of 5 Cases
    Hindawi Case Reports in Otolaryngology Volume 2018, Article ID 4074905, 10 pages https://doi.org/10.1155/2018/4074905 Case Report Head and Neck Schwannomas: A Surgical Challenge—A Series of 5 Cases Ishtyaque Ansari,1 Ashfaque Ansari,2 Arjun Antony Graison ,2 Anuradha J. Patil,3 and Hitendra Joshi2 1Department of Neurosurgery, MGM Medical College & Hospital, Aurangabad, India 2Department of ENT, MGM Medical College & Hospital, Aurangabad, India 3Department of Plastic Surgery, MGM Medical College & Hospital, Aurangabad, India Correspondence should be addressed to Arjun Antony Graison; [email protected] Received 25 September 2017; Accepted 29 January 2018; Published 4 March 2018 Academic Editor: Abrão Rapoport Copyright © 2018 Ishtyaque Ansari et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Schwannomas, also known as neurilemmomas, are benign peripheral nerve sheath tumors. +ey originate from any nerve covered with schwann cell sheath. Schwannomas constitute 25–45% of tumors of the head and neck. About 4% of head and neck schwannomas present as a sinonasal schwannoma. Brachial plexus schwannoma constitute only about 5% of schwannomas. Cervical vagal schwannomas constitute about 2–5% of neurogenic tumors. Methods. We present a case series of 5 patients of schwannomas, one arising from the maxillary branch of trigeminal nerve in the maxillary sinus, second arising from the brachial plexus, third arising from the cervical vagus, and two arising from cervical spinal nerves. Result. Complete extracapsular excision of the tumors was achieved by microneurosurgical technique with preservation of nerve of origin in all except one.
    [Show full text]
  • Tumors of the Brachial Plexus (XI-1)
    E. LOCAL SYNDROMES OF THE UPPER LIMBS AND RELATIVELY GENERALIZED SYNDROMES OF THE UPPER AND LOWER LIMBS GROUP XI: PAIN IN THE SHOULDER, ARM, AND HAND Tumors of the Brachial Plexus (XI-1) Definition Progressive aching, burning pain with paresthesias and sensory and motor impairment in the distribution of a branch or branches of the brachial plexus due to tumor. Site Shoulder and upper limb. System Nervous system. Tumors Benign tumors: schwannoma, neurofibroma. Malignant tumors: malignant schwannoma and fibrosarcoma, metastatic neoplasm or direct invasion from other lesion, neuroblastoma, ganglioneuroma (secondary neoplasia of peripheral nerves occurs frequently in lymphoma, leukemia, multiple myeloma). Breast, lung and thyroid neoplasia frequently involve the brachial plexus. Main Features Incidence: the specific tumors of peripheral nerve are extremely rare. Sex Ratio: there is no sex predilection. Age of Onset: young adulthood. They are more common with von Recklinghausen’s disease. Pain Quality: the pain tends to be constant, gradual in onset, aching, and burning, and associated with paresthesias in the distribution of the pain, progressive wasting of muscles depending upon what groups are involved, and sensory loss. Intensity: severe. Associated Symptoms The pain is generally not affected by activity. There is associated sensory loss and muscle wasting depending upon the area of the brachial plexus involved. Pain relief is often not adequate, even with significant narcotics. Signs and Laboratory Findings The laboratory findings are those of the underlying disease. Signs are loss of reflexes, sensation, and muscle strength in the distribution of the involved portion of the plexus. There may be a local mass. The diagnosis is usually made promptly by X-ray or by CT scan.
    [Show full text]
  • Sciatic Neuropathy from a Giant Hibernoma of the Thigh: a Case Report
    A Case Report & Literature Review Sciatic Neuropathy From a Giant Hibernoma of the Thigh: A Case Report Salim Ersozlu, MD, Orcun Sahin, MD, Ahmet Fevzi Ozgur, MD, and Tolga Akkaya, MD ibernomas—rare, uniformly benign soft-tissue the gastrocnemius/soleus, posterior tibialis, and toe flexors tumors of brown fat—were originally described (tibial nerve-innervated muscles); and sensory abnormali- in 1906 by Merkel.1 These tumors are usually ties throughout the entire sciatic nerve distribution. The found in the scapular2 and posterior cervical common peroneal, posterior tibial, superficial peroneal, Hregions or (more rarely) in the folds of the buttocks or on and sural nerves were electrodiagnostically evaluated, and the thigh.3-5 reduced amplitude in the peroneal and the tibialis poste- Sciatic neuropathy is an infrequently diagnosed focal rior nerves was detected. Sensory nerve conduction of the mononeuropathy. Few case reports of lipomas compressing superficial peroneal and sural nerves in the left leg was the sciatic nerve or its peripheral branches have appeared in less than that in the right leg. These findings confirmed the literature.6-8 The present case report is to our knowledge active motor and sensory sciatic mononeuropathy of the the first on sciatic nerve palsy caused by a hibernoma. left leg. Plain x-rays of the left leg showed a large soft-tissue CASE REPORT mass without calcification. Magnetic resonance imaging A woman in her early 30s was referred to our clinic with a (MRI) of the left leg revealed a well-circumscribed large painless left-side posterior thigh mass that had been slowly soft-tissue mass that was 27 cm at its maximum dimen- enlarging over 5 years.
    [Show full text]
  • Friedreich Ataxia Mouse Models with Progressive Cerebellar and Sensory Ataxia Reveal Autophagic Neurodegeneration in Dorsal Root Ganglia
    The Journal of Neuroscience, February 25, 2004 • 24(8):1987–1995 • 1987 Neurobiology of Disease Friedreich Ataxia Mouse Models with Progressive Cerebellar and Sensory Ataxia Reveal Autophagic Neurodegeneration in Dorsal Root Ganglia Delphine Simon,1 Herve´ Seznec,1 Anne Gansmuller,1 Nade`ge Carelle,1 Philipp Weber,1 Daniel Metzger,1 Pierre Rustin,2 Michel Koenig,1 and He´le`ne Puccio1 1Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Sante´ et de la Recherche Me´dicale (INSERM)/Universite´ Louis Pasteur, 67404 Illkirch cedex, CU de Strasbourg, France, and 2Unite´ de Recherches sur les Handicaps Ge´ne´tiques de l’Enfant, INSERM U393, Hoˆpital Necker-Enfants Malades, 75015 Paris, France Friedreich ataxia (FRDA), the most common recessive ataxia, is characterized by degeneration of the large sensory neurons of the spinal cord and cardiomyopathy. It is caused by severely reduced levels of frataxin, a mitochondrial protein involved in iron–sulfur cluster (ISC) biosynthesis. Through a spatiotemporally controlled conditional gene-targeting approach, we have generated two mouse models for FRDA that specifically develop progressive mixed cerebellar and sensory ataxia, the most prominent neurological features of FRDA. Histological studies showed both spinal cord and dorsal root ganglia (DRG) anomalies with absence of motor neuropathy, a hallmark of the human disease. In addition, one line revealed a cerebellar granule cell loss, whereas both lines had Purkinje cell arborization defects. These lines represent the first FRDA models with a slowly progressive neurological degeneration. We identified an autophagic process as the causative pathological mechanism in the DRG, leading to removal of mitochondrial debris and apparition of lipofuscin deposits.
    [Show full text]
  • Numb Chin Sydrome : a Subtle Clinical Condition with Varied Etiology
    OLGU SUNUMU / CASE REPORT Gülhane Tıp Derg 2015;57: 324 - 327 © Gülhane Askeri Tıp Akademisi 2015 doi: 10.5455/gulhane.44276 Numb chin sydrome : A subtle clinical condition with varied etiology Devika SHETTY (*), Prashanth SHENAI (**), Laxmikanth CHATRA (**), KM VEENA (**), Prasanna Kumar RAO (**), Rachana V PRABHU (**), Tashika KUSHRAJ (**) SUMMARY Introduction One of the rare neurologic symptoms characterized by hypoesthesia or Numb Chin Syndrome (NCS) is a sensory neuropathy cha- paresthesia of the chin and the lower lip, limited to the region served by the mental nerve is known as Numb chin syndrome. Vast etiologic factors have been racterized by altered sensation and numbness in the distribu- implicated in the genesis of numb chin syndrome. Dental, systemic and malignant tion of the mental nerve, a terminal branch of the mandibular etiologies have been well documented. We present a case of a 59 year old female patient who reported with all the classical features of numb chin syndrome. On division of trigeminal nerve. Any dysfunction along the course magnetic resonance imaging, the vascular compression of the trigeminal nerve of trigeminal nerve and its branches, intracranially and ext- root was evident which has been infrequently documented to be associated with racranially either by direct injury or compression of the nerve the condition. We have also briefly reviewed the etiology and pathogenesis of 1 numb chin syndrome and also stressed on the importance of magnetic resonance can predispose to NCS. Various etiologic factors have been imaging as an investigative modality in diagnosing the condition. considered of which dental procedures and dental pathologies Key Words: Numb Chin Syndrome, Mental nerve neuropathy, trigeminal nerve root, are the most common benign causes.
    [Show full text]
  • COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm) Manufacturer: Beijing Institute of Biological Products Co., Ltd
    COVID-19 Vaccine Explainer 24 MAY 20211 COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm) Manufacturer: Beijing Institute of Biological Products Co., Ltd The SARS-CoV-2 Vaccine (VeroCell) is an inactivated vaccine against coronavirus disease 2019 (COVID-19) which stimulates the body’s immune system without risk of causing disease. Once inactivated viruses get presented to the body’s immune system, they stimulate the production of antibodies and make the body ready to respond to an infection with live SARS-CoV-2. This vaccine is adjuvanted (with aluminum hydroxide), to boost the response of the immune system. A large multi-country phase 3 trial has shown that two doses administered at an interval of 21 days had the efficacy of 79% against symptomatic SARS-CoV-2 infection 14 days or more after the second dose. The trial was not designed and powered to demonstrate efficacy against severe disease. Vaccine efficacy against hospitalization was 79%. The median duration of follow up available at the time of review was 112 days. Two efficacy trials are underway. The data reviewed at this time support the conclusion that the known and potential benefits of Sinopharm vaccine outweigh the known and potential risks. Date of WHO Emergency Use Listing (EUL) recommendation: 7 May 2021 Date of prequalification (PQ): currently no information National regulatory authorities (NRAs) can use reliance approaches for in-country authorization of vaccines based on WHO PQ/EUL or emergency use authorizations by stringent regulatory authorities (SRAs). Product characteristics Presentation Fully liquid, inactivated, adjuvanted, preservative-free suspension in vials and AD pre-filled syringes Number of doses Single-dose (one dose 0.5 mL) Vaccine syringe type Two available presentations: and needle size 1.
    [Show full text]
  • Movement Disorders in the Elderly
    MOVEMENT DISORDERS IN THE ELDERLY Eugene C. Lai, M.D., Ph.D. Michael E. DeBakey VA Medical Center Baylor College of Medicine Houston, Texas MOVEMENT DISORDERS Neurologic dysfunctions in which there is either a paucity of voluntary and automatic movements (HYPOKINESIA) or an excess of movement (HYPERKINESIA) or uncontrolled movements (DYSKINESIA) typically unassociated with weakness or spasticity HYPOKINESIAS • Parkinson‟s disease • Secondary Parkinsonism • Parkinson‟s plus syndromes HYPERKINESIAS • Akathisia • Hemifacial spasm • Athetosis • Myoclonus • Ballism • Restless leg syndrome • Chorea • Tics • Dystonia • Tremor COMMON MOVEMENT DISORDERS IN THE ELDERLY • Parkinsonism • Tremor • Gait disorder • Restless leg syndrome • Drug-induced syndrome PARKINSONISM • Parkinson‟s disease • Secondary parkinsonism • Drug-induced parkinsonism • Vascular parkinsonism • Parkinson‟s plus syndromes • Multiple system atrophy • Progressive supranuclear palsy PARKINSON’S DISEASE PARKINSON’S DISEASE Classical Clinical Features • Resting Tremor • Cogwheel Rigidity • Bradykinesia • Postural Instability PARKINSON’S DISEASE Associated Clinical Features • Micrographia • Hypophonia • Hypomimia • Shuffling gait / festination • Drooling • Dysphagia NON-MOTOR COMPLICATIONS IN PARKINSON’S DISEASE • Sleep disturbances • Autonomic dysfunctions • Sensory phenomena • Neuropsychiatric manifestations • Cognitive impairment PARKINSON’S DISEASE General Considerations • The second most common progressive neurodegenerative disorder • The most common neurodegenerative movement
    [Show full text]
  • Thesis Formatted
    Identifying and Treating Neuropathic Pain in Dogs with Syringomyelia Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Ashley C. Hechler, DVM Graduate Program in Comparative Veterinary Medicine The Ohio State University 2019 Thesis Committee Sarah A. Moore, DVM, MS, DACVIM, Advisor Lynette K. Cole, DVM, DACVD Laurie B. Cook, DVM, DACVIM Eric T. Hostnik, DVM, MS, DACVR Copyrighted by Ashley C. Hechler, DVM 2019 Abstract Syringomyelia (SM) is a debilitating condition in the cavalier King Charles spaniel (CKCS) that results in neuropathic pain and diminished quality of life. Von Frey aesthesiometry (VFA) is a method of mechanical quantitative sensory testing that provides an objective sensory threshold (ST) value and can be used to quantify neuropathic pain and monitor response to therapy. The utility of VFA has been previously established in client-owned dogs with acute spinal cord injury and osteoarthritis but the technique has not been evaluated in dogs with SM. The goal of this study was to evaluate ST, as determined by VFA, in dogs with and without SM, to assess the utility of VFA in quantifying NP in SM-affected dogs. We hypothesized the SM- affected CKCS would have lower ST values consistent with hyperesthesia, when compared to control CKCS. Additionally, we hypothesized that ST values in SM-affected dogs would be inversely correlated with syrinx size on MRI and with owner-derived clinical sign scores. ST values for the thoracic and pelvic limbs differed significantly between SM-affected and control CKCS (p=0.027; p=0.0396 respectively).
    [Show full text]
  • The Clinical Approach to Movement Disorders Wilson F
    REVIEWS The clinical approach to movement disorders Wilson F. Abdo, Bart P. C. van de Warrenburg, David J. Burn, Niall P. Quinn and Bastiaan R. Bloem Abstract | Movement disorders are commonly encountered in the clinic. In this Review, aimed at trainees and general neurologists, we provide a practical step-by-step approach to help clinicians in their ‘pattern recognition’ of movement disorders, as part of a process that ultimately leads to the diagnosis. The key to success is establishing the phenomenology of the clinical syndrome, which is determined from the specific combination of the dominant movement disorder, other abnormal movements in patients presenting with a mixed movement disorder, and a set of associated neurological and non-neurological abnormalities. Definition of the clinical syndrome in this manner should, in turn, result in a differential diagnosis. Sometimes, simple pattern recognition will suffice and lead directly to the diagnosis, but often ancillary investigations, guided by the dominant movement disorder, are required. We illustrate this diagnostic process for the most common types of movement disorder, namely, akinetic –rigid syndromes and the various types of hyperkinetic disorders (myoclonus, chorea, tics, dystonia and tremor). Abdo, W. F. et al. Nat. Rev. Neurol. 6, 29–37 (2010); doi:10.1038/nrneurol.2009.196 1 Continuing Medical Education online 85 years. The prevalence of essential tremor—the most common form of tremor—is 4% in people aged over This activity has been planned and implemented in accordance 40 years, increasing to 14% in people over 65 years of with the Essential Areas and policies of the Accreditation Council age.2,3 The prevalence of tics in school-age children and for Continuing Medical Education through the joint sponsorship of 4 MedscapeCME and Nature Publishing Group.
    [Show full text]
  • Ataxia in Children: Early Recognition and Clinical Evaluation Piero Pavone1,6*, Andrea D
    Pavone et al. Italian Journal of Pediatrics (2017) 43:6 DOI 10.1186/s13052-016-0325-9 REVIEW Open Access Ataxia in children: early recognition and clinical evaluation Piero Pavone1,6*, Andrea D. Praticò2,3, Vito Pavone4, Riccardo Lubrano5, Raffaele Falsaperla1, Renata Rizzo2 and Martino Ruggieri2 Abstract Background: Ataxia is a sign of different disorders involving any level of the nervous system and consisting of impaired coordination of movement and balance. It is mainly caused by dysfunction of the complex circuitry connecting the basal ganglia, cerebellum and cerebral cortex. A careful history, physical examination and some characteristic maneuvers are useful for the diagnosis of ataxia. Some of the causes of ataxia point toward a benign course, but some cases of ataxia can be severe and particularly frightening. Methods: Here, we describe the primary clinical ways of detecting ataxia, a sign not easily recognizable in children. We also report on the main disorders that cause ataxia in children. Results: The causal events are distinguished and reported according to the course of the disorder: acute, intermittent, chronic-non-progressive and chronic-progressive. Conclusions: Molecular research in the field of ataxia in children is rapidly expanding; on the contrary no similar results have been attained in the field of the treatment since most of the congenital forms remain fully untreatable. Rapid recognition and clinical evaluation of ataxia in children remains of great relevance for therapeutic results and prognostic counseling. Keywords: Ataxia, Diagnostic maneuvers, Acute cerebellitis, Cerebellar syndrome, Cerebellar malformations Background Clinical signs in cerebellar ataxic patients are related to Ataxia in children is a common clinical sign of various impaired localization.
    [Show full text]
  • Ataxia and Tremor in People with Multiple Sclerosis (MS)
    for health professionals Ataxia and tremor in people with multiple sclerosis (MS) Freecall: 1800 042 138 www.msaustralia.org.au MS PRACTICE // ATAXIA AND TREMOR IN PEOPLE WITH MULTIPLE SCLEROSIS Ataxia and tremor in people with multiple sclerosis (MS) Ataxia and tremor are common yet difficult symptoms to manage in people with MS ― often requiring the involvement of a multidisciplinary team. Early intervention is important in order to address both the functional and psychological issues associated with these symptoms. Freecall: 1800 042 138 www.msaustralia.org.au MS PRACTICE // ATAXIA AND TREMOR IN PEOPLE WITH MULTIPLE SCLEROSIS 01 Contents Page 1.0 Definitions 02 2.0 Incidence and impact 3.0 Pathophysiology and clinical characteristics 3.1 Ataxia 3.2 Tremor 03 4.0 Assessment 5.0 Management 04 5.1 Physiotherapy 5.2 Pharmacotherapy 05 5.3 Surgical intervention 06 6.0 Summary Freecall: 1800 042 138 www.msaustralia.org.au MS PRACTICE // AtaXIA AND TREMOR IN PEOPLE WITH MULTIPLE SCLEROSIS 02 1.0 Definitions Ataxia Tremor Ataxia is a term used to describe a number of Tremor is defined as a rhythmic, involuntary, oscillating abnormal movements that may occur during the movement of a body part. There are two main execution of voluntary movements. They include, but classifications of tremor ― resting tremor and action are not limited to, incoordination, delay in movement, tremor. Resting tremor is present in a body part that dysmetria (inaccuracy in achieving a target), is completely supported against gravity and is not dysdiadochokinesia (inability
    [Show full text]